Stephane Rinfret

Stephane Rinfret practices at Erlanger Western Carolina Hospital in Murphy, North Carolina, part of Erlanger Health.

Stephane Rinfret's NPI, 1679168470, was assigned on March 3, 2021. Stephane Rinfret holds Georgia license 87689.

Stephane Rinfret's primary practice is Erlanger Western Carolina Hospital, at 3990 East US Highway 64 Alt, Murphy, NC 28906 in Cherokee County. The practice phone is (828) 837-8161. Stephane Rinfret also practices at Erlanger Western Carolina Hospital, 4066 W Us-64, Murphy, NC 28906.

Stephane Rinfret's primary practice is Erlanger Western Carolina Hospital in Murphy, North Carolina, part of Erlanger Health. Stephane Rinfret is also affiliated with Northeast Georgia Medical Center Gainesville. The medical group on file is Georgia Heart Institute. Dmand AI also links Stephane Rinfret to 4 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Stephane Rinfret practices, 8 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Stephane Rinfret's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Stephane Rinfret is licensed in Georgia.

CMS data shows 805 Medicare services from Stephane Rinfret across 19 procedure codes in 2024, for 436 Medicare patients. Medicare paid $67,670 for them.

CMS counts 436 Medicare patients who saw Stephane Rinfret in 2024. The largest group is 75 to 84, with 176 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 13% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Stephane Rinfret's median patient age at 73, with 44% women.

In 2024, Stephane Rinfret wrote 155 Medicare Part D claims for 51 patients. 86% of them were for generic drugs. CMS names the drug for 74 of them, across 4 drugs with 11 or more claims each, at $11,116 in total drug cost. In 2023, CMS named 105 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Stephane Rinfret for performance year 2024, reported through an alternative payment model (APM). Stephane Rinfret accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 113 procedures of coronary angioplasty and stenting by Stephane Rinfret, more than 97% of the clinicians it reports for that procedure.

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 63 papers to Stephane Rinfret, published from 2011 to 2025. 2023 was the busiest year, with 15. The most frequent topics are Percutaneous Coronary Intervention, Coronary Occlusion and Coronary Angiography. Stephane Rinfret has published most often in Catheter Cardiovasc Interv. Stephane Rinfret's most frequent co-authors are Khaldoon Alaswad, MD, William J. Nicholson, MD and Wissam A. Jaber, MD.

Dmand AI links Stephane Rinfret to 1 clinical trial. Conditions studied include Constriction, Pathologic and Coronary Artery Disease.

CMS Open Payments shows 251 general payments to Stephane Rinfret from 22 drug and device companies from 2021 to 2025. Consulting fees make up the largest share, 35% of the total. Teleflex LLC paid the most, $16,931.